These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 31057090)

  • 1. Exploration of good and bad structural fingerprints for inhibition of indoleamine-2,3-dioxygenase enzyme in cancer immunotherapy using Monte Carlo optimization and Bayesian classification QSAR modeling.
    Jain S; Bhardwaj B; Amin SA; Adhikari N; Jha T; Gayen S
    J Biomol Struct Dyn; 2020 Apr; 38(6):1683-1696. PubMed ID: 31057090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of potential indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors by an FBG-based 3D QSAR pharmacophore model.
    Zhang L; Lai F; Chen X; Xiao Z
    J Mol Graph Model; 2020 Sep; 99():107628. PubMed ID: 32387857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.
    Prendergast GC; Malachowski WJ; Mondal A; Scherle P; Muller AJ
    Int Rev Cell Mol Biol; 2018; 336():175-203. PubMed ID: 29413890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of structural fingerprints for ABCG2 inhibition by using Monte Carlo optimization, Bayesian classification, and structural and physicochemical interpretation (SPCI) analysis.
    Ghosh K; Bhardwaj B; Amin SA; Jha T; Gayen S
    SAR QSAR Environ Res; 2020 Jun; 31(6):439-455. PubMed ID: 32539470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
    Röhrig UF; Majjigapu SR; Reynaud A; Pojer F; Dilek N; Reichenbach P; Ascencao K; Irving M; Coukos G; Vogel P; Michielin O; Zoete V
    J Med Chem; 2021 Feb; 64(4):2205-2227. PubMed ID: 33557523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
    Röhrig UF; Majjigapu SR; Vogel P; Reynaud A; Pojer F; Dilek N; Reichenbach P; Ascenção K; Irving M; Coukos G; Michielin O; Zoete V
    J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1773-1811. PubMed ID: 35758198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent discovery of indoleamine-2,3-dioxygenase 1 inhibitors targeting cancer immunotherapy.
    Weng T; Qiu X; Wang J; Li Z; Bian J
    Eur J Med Chem; 2018 Jan; 143():656-669. PubMed ID: 29220788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): A promising direction in cancer immunotherapy.
    Zhang Y; Hu Z; Zhang J; Ren C; Wang Y
    Eur J Med Chem; 2022 Aug; 238():114524. PubMed ID: 35696861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Good and bad molecular fingerprints for human rhinovirus 3C protease inhibition: identification, validation, and application in designing of new inhibitors through Monte Carlo-based QSAR study.
    Jain S; Amin SA; Adhikari N; Jha T; Gayen S
    J Biomol Struct Dyn; 2020 Jan; 38(1):66-77. PubMed ID: 30646829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
    Tomek P; Palmer BD; Flanagan JU; Sun C; Raven EL; Ching LM
    Eur J Med Chem; 2017 Jan; 126():983-996. PubMed ID: 28011425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spiro-Oxindole Skeleton Compounds Are Efficient Inhibitors for Indoleamine 2,3-Dioxygenase 1: An Attractive Target for Tumor Immunotherapy.
    Yan D; Xu J; Wang X; Zhang J; Zhao G; Lin Y; Tan X
    Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563059
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting IDO pathways to treat cancer: lessons from the ECHO-301 trial and beyond.
    Muller AJ; Manfredi MG; Zakharia Y; Prendergast GC
    Semin Immunopathol; 2019 Jan; 41(1):41-48. PubMed ID: 30203227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
    Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
    Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
    Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
    J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.
    Moyer BJ; Rojas IY; Murray IA; Lee S; Hazlett HF; Perdew GH; Tomlinson CR
    Toxicol Appl Pharmacol; 2017 May; 323():74-80. PubMed ID: 28336214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of structural fingerprints for
    Mondal D; Ghosh K; Baidya ATK; Gantait AM; Gayen S
    Toxicol Mech Methods; 2020 May; 30(4):257-265. PubMed ID: 31876230
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy.
    Tang K; Wu YH; Song Y; Yu B
    J Hematol Oncol; 2021 Apr; 14(1):68. PubMed ID: 33883013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors by virtual screening.
    Zhou Y; Peng J; Li P; Du H; Li Y; Li Y; Zhang L; Sun W; Liu X; Zuo Z
    Comput Biol Chem; 2019 Feb; 78():306-316. PubMed ID: 30616156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery and optimization of substituted oxalamides as novel heme-displacing IDO1 inhibitors.
    Steeneck C; Kinzel O; Anderhub S; Hornberger M; Pinto S; Morschhaeuser B; Albers M; Sonnek C; Czekańska M; Hoffmann T
    Bioorg Med Chem Lett; 2021 Feb; 33():127744. PubMed ID: 33333163
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Yang D; Zhang S; Fang X; Guo L; Hu N; Guo Z; Li X; Yang S; He JC; Kuang C; Yang Q
    J Med Chem; 2019 Oct; 62(20):9161-9174. PubMed ID: 31580660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.